Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
Independent and Interactive Effect of CYPs and GSTs Genetic Variants and Tobacco Smoking on the Risk of Non-Small Cell Lung Carcinoma.
Pathak AK et al.
Archives of Medical Research, 2021
Genome sequencing analysis of blood cells identifies germline haplotypes strongly associated with drug resistance in osteosarcoma patients.
Bhuvaneshwar K et al.
Bmc Cancer, 2019
HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers.
Hua F et al.
Thoracic Cancer, 2019
Oxidation of 1-chloropyrene by human CYP1 family and CYP2A subfamily cytochrome P450 enzymes: catalytic roles of two CYP1B1 and five CYP2A13 allelic variants.
Shimada T et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2018
Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation.
Kumondai M et al.
Drug Metabolism and Pharmacokinetics, 2018
In vitro functional analysis of human cytochrome P450 2A13 genetic variants: P450 2A13*2, *3, *4, and *10.
Kim V et al.
Journal of Toxicology and Environmental Health. Part A, 2018
CYP2A13 Genetic Polymorphisms in Relation to the Risk of Bladder Cancer in Japanese Smokers.
Kumondai M et al.
Biological & Pharmaceutical Bulletin, 2016
Pulmonary expression of CYP2A13 and ABCB1 is regulated by FOXA2, and their genetic interaction is associated with lung cancer.
Xiang C et al.
Faseb Journal : Official Publication of the Federation of American Societies for Experimental Biology, 2015
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism-related enzymes gene polymorphisms, NNK metabolites levels and urothelial carcinoma.
Chung CJ et al.
Toxicology Letters, 2013
An investigation of the catalytic activity of CYP2A13*4 with coumarin and polymorphisms of CYP2A13 in a Chinese Han population.
Liu T et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2012
Interactions among genetic variants in tobacco metabolizing genes and smoking are associated with head and neck cancer susceptibility in North Indians.
Sharma R et al.
Dna and Cell Biology, 2011
Polymorphisms in CYP2A13 and UGT1A7 genes and head and neck cancer susceptibility in North Indians.
Sharma R et al.
Oral Diseases, 2010
Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment.
Rodriguez-Antona C et al.
Human Genetics, 2010
Mechanisms of differential expression of the CYP2A13 7520C and 7520G alleles in human lung: allelic expression analysis for CYP2A13 heterogeneous nuclear RNA, and evidence for the involvement of multiple cis-regulatory single nucleotide polymorphisms.
Wu H et al.
Pharmacogenetics and Genomics, 2009
CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences.
Timofeeva MN et al.
Carcinogenesis, 2009
Molecular genetics of nicotine metabolism.
Mwenifumbo JC et al.
Handbook of Experimental Pharmacology, 2009
Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
Song DK et al.
Cancer Detection and Prevention, 2009
Characterization of CYP2A13*2, a variant cytochrome P450 allele previously found to be associated with decreased incidences of lung adenocarcinoma in smokers.
D'Agostino J et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008
Functional characterization of CYP2A13 polymorphisms.
Schlicht KE et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2007
Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
Nakajima M
Current Opinion in Molecular Therapeutics, 2007
Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2007
The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant.
Wang SL et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology, 2006
Cytochrome P2A13 and P1A1 gene polymorphisms are associated with the occurrence of uterine leiomyoma.
Herr D et al.
Archives of Gynecology and Obstetrics, 2006
Japanese single nucleotide polymorphism database for 267 possible drug-related genes.
Iida A et al.
Cancer Science, 2006
The relationship between the pharmacology of antiepileptic drugs and human gene variation: an overview.
Ferraro TN et al.
Epilepsy & Behavior : E&b, 2005
Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1.
Roos PH et al.
Expert Opinion on Drug Metabolism & Toxicology, 2005
CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations.
Cauffiez C et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2005
Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers.
Fujieda M et al.
Carcinogenesis, 2004
Development of a real-time polymerase chain reaction-based method for the measurement of relative allelic expression and identification of CYP2A13 alleles with decreased expression in human lung.
Zhang X et al.
The Journal of Pharmacology and Experimental Therapeutics, 2004
Genetic polymorphisms of CYP2A13 and its relationship to nasopharyngeal carcinoma in the Cantonese population.
Jiang JH et al.
Journal of Translational Medicine, 2004
Arg257Cys polymorphism of CYP2A13 in a Chinese population.
Cheng XY et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2004
Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H et al.
Cancer Research, 2003
Single nucleotide polymorphisms of the human cyp2a13 gene: evidence for a null allele.
Zhang X et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2003
[SNP collection, pharmacogenomics, and the future of drug therapy].
Iida A et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy, 2002
Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant.
Zhang X et al.
The Journal of Pharmacology and Experimental Therapeutics, 2002